Monoclonal Antibodies for Clinical Use

Research Resources: Antibody

The International Nonproprietary Names (INN) recommends to name murine antibodies to end in “–omab”, chimeric antibodies to end in “-ximab”, humanized antibodies to end in “–zumab”, and fully human antibodies with end in “–umab”. The list includes therapeutic, diagnostic, and preventive monoclonal antibodies that are approved, investigational drugs, and drugs that have been withdrawn from the market.

List of Monoclonal Antibodies for Clinical Use


Name	Trade Name	Type	Source	Target Antigen	Clinical Use
Abagovomab		mab	mouse	CA-125 (imitation)	ovarian cancer
Abciximab	ReoPro®	Fab	chimeric	CD41 (integrin α-IIb)	platelet aggregation inhibitor
Actoxumab		mab	human	Clostridium difficile	Clostridium difficile infection
Adalimumab	Humira®	mab	human	TNF-α	rheumatoid arthritis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis
Adecatumumab		mab	human	EpCAM	prostate and breast cancer
Ado-trastuzumab emtansine	Kadcyla®	mab (ADC)	humanized	HER2/neu	breast cancer
Afelimomab		F(ab')₂	mouse	TNF-α	sepsis
Afutuzumab		mab	humanized	CD20	lymphoma
Alacizumab pegol		F(ab')₂	humanized	VEGFR2	cancer
Alemtuzumab	Campath-1H®, MabCampath®	mab	humanized	CD52	CLL, CTCL
Alirocumab		mab	human	NARP-1	hypercholesterolemia
Altumomab pentetate	Hybri-ceaker®	mab	mouse	CEA	colorectal cancer (diagnosis)
Amatuximab		mab	chimeric	Mesothelin	cancer
Anatumomab mafenatox		Fab	mouse	TAG-72	non-small cell lung carcinoma
Anifrolumab		mab	human	Interferon α/β receptor	systemic lupus erythematosus
Anrukinzumab		mab	humanized	IL-13	?
Apolizumab		mab	humanized	HLA-DR	hematological cancers
Arcitumomab	CEA-Scan®	Fab'	mouse	CEA	gastrointestinal cancers (diagnosis)
Aselizumab		mab	humanized	L-selectin (CD62L)	severely injured patients
Atezolizumab	Tecentriq®	mab	humanized	PD-L1	lung cancer, bladder cancer
Atinumab		mab	human	RTN4	?
Atlizumab (Tocilizumab)	Actemra®, RoActemra®	mab	humanized	IL-6 receptor	rheumatoid arthritis
Atorolimumab		mab	human	Rhesus factor	hemolytic disease of the newborn
Bapineuzumab		mab	humanized	β-amyloid	Alzheimer's disease
Basiliximab	Simulect®	mab	chimeric	CD25	prevention of organ transplant rejections
Bavituximab		mab	chimeric	Phosphatidylserine	cancer, viral infections
Bectumomab	LymphoScan®	Fab'	mouse	CD22	non-Hodgkin's lymphoma (detection)
Belimumab	Benlysta®, LymphoStat-B	mab	human	BAFF	SLE, non-Hodgkin lymphoma
Benralizumab		mab	humanized	CD125	asthma
Bertilimumab		mab	human	CCL11 (eotaxin-1)	severe allergic disorders
Besilesomab	Scintimun®	mab	mouse	CEA-related antigen	inflammatory lesions and metastases (detection)
Bevacizumab	Avastin®	mab	humanized	VEGF-A	metastatic cancer
Bezlotoxumab		mab	human	Clostridium difficile	Clostridium difficile infection
Biciromab	FibriScint®	Fab'	mouse	Fibrin II, β chain	thromboembolism (diagnosis)
Bimagrumab		mab	human	ACVRIIB	myostatin inhibitor
Bivatuzumab mertansine		mab	humanized	CD44 v6	squamous cell carcinoma
Blinatumomab	Blincyto®	scFv (BiTE)	mouse	CD19, CD3	cancer
Blosozumab		mab	humanized	SOST	osteoporosis
Bococizumab		mab	humanized	PCSK9	hypocholesterolemia
Brentuximab vedotin	Adcetris®	mab (ADC)	chimeric	CD30 (TNFRSF8)	hematologic cancers (Hodgkin lymphoma)
Briakinumab		mab	human	IL-12, IL-23	psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab		mab	human	IL-17	inflammatory diseases
Canakinumab	Ilaris®	mab	human	IL-1	rheumatoid arthritis
Cantuzumab mertansine		mab	humanized	Mucin CanAg	colorectal cancer etc.
Cantuzumab ravtansine		mab	humanized	MUC1	cancers
Caplacizumab		mab	humanized	VWF	?
Capromab pendetide	Prostascint®	mab	mouse	PMSA	prostate cancer (detection)
Carlumab		mab	human	MCP-1	oncology/immune indications
Catumaxomab	Removab®	3funct	rat/mouse hybrid	EpCAM, CD3	ovarian cancer, malignant ascites, gastric cancer
Cedelizumab		mab	humanized	CD4	prevention of organ transplant rejections, treatment of autoimmune diseases
Certolizumab pegol	Cimzia®	Fab'	humanized	TNF-α	Crohn's disease
Cetuximab	Erbitux®	mab	chimeric	EGFR	metastatic colorectal cancer and head and neck cancer
Citatuzumab bogatox		Fab	humanized	EpCAM	ovarian cancer and other solid tumors
Cixutumumab		mab	human	IGF1R	solid tumors
Clazakizumab		mab	humanized	Oryctolagus cuniculus	rheumatoid arthritis
Clenoliximab		mab	chimeric	CD4	rheumatoid arthritis
Clivatuzumab tetraxetan	hPAM4-Cide	mab	humanized	MUC1	pancreatic cancer
Conatumumab		mab	human	TRAIL-R2	cancer
Concizumab		mab	humanized	TFPI	bleeding
Crenezumab		mab	humanized	1-40-β-amyloid	Alzheimer's disease
Dacetuzumab		mab	humanized	CD40	hematologic cancers
Daclizumab	Zenapax®	mab	humanized	CD25	prevention of organ transplant rejections
Dalotuzumab		mab	humanized	IGF1R	cancer etc.
Daratumumab	Darzalex®	mab	human	CD38	multiple myeloma
Demcizumab		mab	humanized	DLL4	cancer
Denosumab	Prolia®/Xgeva®	mab	human	RANKL	osteoporosis, bone metastases etc.
Detumomab		mab	mouse	B-lymphoma cell	lymphoma
Dorlimomab aritox		F(ab')₂	mouse	?	?
Drozitumab		mab	human	DR5	cancer etc.
Duligotumab		mab	human	HER3	?
Dupilumab		mab	human	IL4	atopic diseases
Dusigitumab		mab	human	ILGF2	cancer
Ecromeximab		mab	chimeric	GD3 ganglioside	malignant melanoma
Eculizumab	Soliris®	mab	humanized	C5	paroxysmal nocturnal hemoglobinuria
Edobacomab		mab	mouse	Endotoxin	sepsis caused by Gram-negative bacteria
Edrecolomab	Panorex®	mab	mouse	EpCAM	colorectal carcinoma
Efalizumab	Raptiva®	mab	humanized	LFA-1 (CD11a)	psoriasis (blocks T-cell migration)
Efungumab	Mycograb®	scFv	human	Hsp90	invasive Candida infection
Eldelumab		mab	human	Interferon γ-induced protein	Crohn's disease, ulcerative colitis
Elotuzumab	Elmplicit®	mab	humanized	SLAMF7	multiple myeloma
Elsilimomab		mab	mouse	IL-6	?
Enavatuzumab		mab	humanized	TWEAK receptor	cancer etc.
Enlimomab pegol		mab	mouse	ICAM-1 (CD54)	?
Enokizumab		mab	humanized	IL9	asthma
Enoticumab		mab	human	DLL4	?
Ensituximab		mab	chimeric	5AC	cancer
Epitumomab cituxetan		mab	mouse	Episialin	?
Epratuzumab		mab	humanized	CD22	cancer, SLE
Erlizumab		F(ab')₂	humanized	ITGB2 (CD18)	heart attack, stroke, traumatic shock
Ertumaxomab	Rexomun®	3funct	rat/mouse hybrid	HER2/neu, CD3	breast cancer etc.
Etaracizumab	Abegrin®	mab	humanized	Integrin α_vβ₃	melanoma, prostate cancer, ovarian cancer etc.
Etrolizumab		mab	humanized	Integrin α₇ β₇	inflammatory bowel disease
Evolocumab		mab	human	PCSK9	hypocholesterolemia
Exbivirumab		mab	human	Hepatitis B surface antigen	hepatitis B
Fanolesomab	NeutroSpec®	mab	mouse	CD15	appendicitis (diagnosis)
Faralimomab		mab	mouse	Interferon receptor	?
Farletuzumab		mab	humanized	Folate receptor 1	ovarian cancer
Fasinumab		mab	human	HNGF	?
Felvizumab		mab	humanized	Respiratory syncytial virus	respiratory syncytial virus infection
Fezakinumab		mab	human	IL-22	rheumatoid arthritis, psoriasis
Ficlatuzumab		mab	humanized	HGF	cancer etc.
Figitumumab		mab	human	IGF-1 receptor	adrenocortical carcinoma, non-small cell lung carcinoma etc.
Flanvotumab		mab	human	Glycoprotein 75	melanoma
Fontolizumab	HuZAF®	mab	humanized	IFN-γ	Crohn's disease etc.
Foralumab		mab	human	CD3ε	?
Foravirumab		mab	human	Rabies virus glycoprotein	rabies (prophylaxis)
Fresolimumab		mab	human	TGF-β	idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Fulranumab		mab	human	NGF	pain
Futuximab		mab	chimeric	EGFR	?
Galiximab		mab	chimeric	CD80	B-cell lymphoma
Ganitumab		mab	human	IGF-I	cancer
Gantenerumab		mab	human	β-amyloid	Alzheimer's disease
Gavilimomab		mab	mouse	CD147 (basigin)	graft versus host disease
Gemtuzumab ozogamicin	Mylotarg®	mab (ADC)	humanized	CD33	acute myelogenous leukemia (withdrawn from the market)
Gevokizumab		mab	humanized	IL-1β	diabetes etc.
Girentuximab	Rencarex®	mab	chimeric	Carbonic anhydrase 9 (CA-IX)	clear cell renal cell carcinoma
Glembatumumab vedotin		mab	human	GPNMB	melanoma, breast cancer
Golimumab	Simponi®	mab	human	TNF-α	rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab		mab	chimeric	CD23 (IgE receptor)	allergic asthma
Guselkumab		mab	human	IL23p19	psoriasis
Ibalizumab		mab	humanized	CD4	HIV infection
Ibritumomab tiuxetan	Zevalin®	mab	mouse	CD20	non-Hodgkin's lymphoma
Icrucumab		mab	human	VEGFR-1	cancer etc.
Igovomab	Indimacis-125®	F(ab')₂	mouse	CA-125	ovarian cancer (diagnosis)
Imciromab	Myoscint®	mab	mouse	Cardiac myosin	cardiac imaging
Imgatuzumab		mab	humanized	EGFR	cancer
Inclacumab		mab	human	Selectin P	?
Indatuximab ravtansine		mab	chimeric	SDC1	cancer
Infliximab	Remicade®	mab	chimeric	TNF-α	rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab		mab	human	CD51	solid tumors (prostate cancer, melanoma)
Inolimomab		mab	mouse	CD25	graft versus host disease
Inotuzumab ozogamicin		mab	humanized	CD22	cancer
Ipilimumab	Yervoy®	mab	human	CD152	melanoma
Iratumumab		mab	human	CD30 (TNFRSF8)	Hodgkin's lymphoma
Itolizumab		mab	humanized	CD6	?
Ixekizumab		mab	humanized	IL-17A	autoimmune diseases
Keliximab		mab	chimeric	CD4	chronic asthma
Labetuzumab	CEA-Cide®	mab	humanized	CEA	colorectal cancer
Lambrolizumab (Pembrolizumab)	Keytruda®	mab	humanized	PD-1	antineoplastic agent
Lampalizumab		mab	humanized	CFD	?
Lebrikizumab		mab	humanized	IL-13	asthma
Lemalesomab		mab	mouse	NCA-90 (granulocyte antigen)	diagnostic agent
Lerdelimumab		mab	human	TGFβ2	reduction of scarring after glaucoma surgery
Lexatumumab		mab	human	TRAIL-R2	cancer
Libivirumab		mab	human	Hepatitis B surface antigen	hepatitis B
Ligelizumab		mab	humanized	IGHE	?
Lintuzumab		mab	humanized	CD33	cancer
Lirilumab		mab	human	KIR2D	?
Lodelcizumab		mab	humanized	PCSK9	hypercholesterolemia
Lorvotuzumab mertansine		mab	humanized	CD56	cancer
Lucatumumab		mab	human	CD40	multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lumiliximab		mab	chimeric	CD23 (IgE receptor)	chronic lymphocytic leukemia
Mapatumumab		mab	human	TRAIL-R1	cancer
Margetuximab		mab	humanized	ch4D5	cancer
Maslimomab		?	mouse	T-cell receptor	?
Mavrilimumab		mab	human	GMCSF receptor α-chain	rheumatoid arthritis
Matuzumab		mab	humanized	EGFR	colorectal, lung and stomach cancer
Mepolizumab	Bosatria®	mab	humanized	IL-5	asthma and white blood cell diseases
Metelimumab		mab	human	TGF beta 1	systemic scleroderma
Milatuzumab		mab	humanized	CD74	multiple myeloma and other hematological malignancies
Minretumomab		mab	mouse	TAG-72	?
Mitumomab		mab	mouse	GD3 ganglioside	small cell lung carcinoma
Mogamulizumab		mab	humanized	CCR4	cancer
Morolimumab		mab	human	Rhesus factor	?
Motavizumab	Numax®	mab	humanized	Respiratory syncytial virus	respiratory syncytial virus (prevention)
Moxetumomab pasudotox		mab	mouse	CD22	cancer
Muromonab-CD3	Orthoclone OKT3	mab	mouse	CD3	prevention of organ transplant rejections
Nacolomab tafenatox		Fab	mouse	C242 antigen	colorectal cancer
Namilumab		mab	human	CSF2	?
Naptumomab estafenatox		Fab	mouse	5T4	non-small cell lung carcinoma, renal cell carcinoma
Narnatumab		mab	human	RON	cancer
Natalizumab	Tysabri®	mab	humanized	Integrin α4	multiple sclerosis, Crohn's disease
Nebacumab		mab	human	Endotoxin	sepsis
Necitumumab	Portrazza®	mab	human	EGFR	non-small cell lung carcinoma
Nerelimomab		mab	mouse	TNF-α	?
Nesvacumab		mab	human	Angiopoietin 2	cancer
Nimotuzumab	Theracim®, Theraloc®	mab	humanized	EGFR	squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nivolumab	Opdivo®	mab	human	PD-1	melanoma, lung cancer, kidney cancer
Nofetumomab merpentan	Verluma®	Fab	mouse	?	cancer (diagnosis)
Obinutuzumab	Gazyva®	mab	humanized	CD20	B-CLL, lymphoma
Ocaratuzumab		mab	humanized	CD20	cancer
Ocrelizumab		mab	humanized	CD20	rheumatoid arthritis, lupus erythematosus etc.
Odulimomab		mab	mouse	LFA-1 (CD11a)	prevention of organ transplant rejections, immunological diseases
Ofatumumab	Arzerra®	mab	human	CD20	chronic lymphocytic leukemia etc.
Olaratumab	Lartruvo®	mab	human	PDGF-Rα	cancer
Olokizumab		mab	humanized	IL6	?
Omalizumab	Xolair®	mab	humanized	IgE Fc region	allergic asthma
Onartuzumab		mab	humanized (monovalent)	MET, c-Met, HGF/SF-R	cancer
Ontuxizumab		mab	chimeric/humanized	TEM1	cancer
Oportuzumab monatox		scFv	humanized	EpCAM	cancer
Oregovomab	OvaRex®	mab	mouse	CA-125	ovarian cancer
Orticumab		mab	human	oxLDL	?
Otelixizumab		mab	chimeric/humanized	CD3	diabetes mellitus type 1
Oxelumab		mab	human	OX-40	asthma
Ozanezumab		mab	humanized	NOGO-A	ALS and multiple sclerosis
Ozoralizumab		mab	humanized	TNF-α	inflammation
Pagibaximab		mab	chimeric	Lipoteichoic acid	sepsis (Staphylococcus)
Palivizumab	Synagis®, Abbosynagis®	mab	humanized	F protein of respiratory syncytial virus	respiratory syncytial virus (prevention)
Panitumumab	Vectibix®	mab	human	EGFR	colorectal cancer
Panobacumab		mab	human	Pseudomonas aeruginosa	Pseudomonas aeruginosa infection
Parsatuzumab		mab	human	EGFL7	cancer
Pascolizumab		mab	humanized	IL-4	asthma
Pateclizumab		mab	humanized	LTA	?
Patritumab		mab	human	HER3	cancer
Pembrolizumab	Keytruda®	mab	humanized	PD-1	Melanoma, lung cancer
Pemtumomab	Theragyn®	?	mouse	MUC1	cancer
Perakizumab		mab	humanized	IL17A	arthritis
Pertuzumab	Omnitarg/Perjeta®	mab	humanized	HER2/neu	cancer
Pexelizumab		scFv	humanized	C5	reduction of side effects of cardiac surgery
Pidilizumab		mab	humanized	PD-1	cancer and infectious diseases
Pinatuzumab vedotin		mab	humanized	CD22	cancer
Pintumomab		mab	mouse	Adenocarcinoma antigen	adenocarcinoma (imaging)
Placulumab		mab	human	TNF	?
Polatuzumab vedotin		mab	humanized	CD79B	?
Ponezumab		mab	humanized	β-amyloid	Alzheimer's disease
Priliximab		mab	chimeric	CD4	Crohn's disease, multiple sclerosis
Pritoxaximab		mab	chimeric	E. coli shiga toxin type-1	?
Pritumumab		mab	human	Vimentin	brain cancer
Quilizumab		mab	humanized	IGHE	?
Racotumomab		mab	mouse	N-glycolylneuraminic acid	cancer
Radretumab		mab	human	Fibronectin extra domain-B	cancer
Rafivirumab		mab	human	Rabies virus glycoprotein	rabies (prophylaxis)
Ramucirumab	Cyramza®	mab	human	VEGFR2	solid tumors (NSCLC, gastric)
Ranibizumab	Lucentis®	Fab	humanized	VEGF-A	macular degeneration (wet form)
Raxibacumab		mab	human	Anthrax toxin, protective antigen	anthrax (prophylaxis and treatment)
Regavirumab		mab	human	Cytomegalovirus glycoprotein B	cytomegalovirus infection
Reslizumab		mab	humanized	IL-5	inflammations of the airways, skin and gastrointestinal tract
Rilotumumab		mab	human	HGF	solid tumors
Rituximab	MabThera, Rituxan®	mab	chimeric	CD20	lymphomas, leukemias, some autoimmune disorders
Robatumumab		mab	human	IGF-1 receptor	cancer
Roledumab		mab	human	RHD	?
Romosozumab		mab	humanized	Scleroscin	osteoporosis
Rontalizumab		mab	humanized	IFN-α	systemic lupus erythematosus
Rovelizumab	LeukArrest®	mab	humanized	CD11, CD18	haemorrhagic shock etc.
Ruplizumab	Antova®	mab	humanized	CD154 (CD40L)	rheumatic diseases
Samalizumab		mab	humanized	CD200	cancer
Sarilumab		mab	human	IL6	rheumatoid arthritis, ankylosing spondylitis
Satumomab pendetide		mab	mouse	TAG-72	cancer (diagnosis)
Secukinumab		mab	human	IL-17A	uveitis, rheumatoid arthritis psoriasis
Seribantumab		mab	human	ERBB3, HER3	cancer
Setoxaximab		mab	chimeric	E. coli shiga toxin type-1	?
Sevirumab		?	human	Cytomegalovirus	cytomegalovirus infection
Sibrotuzumab		mab	humanized	FAP	cancer
Sifalimumab		mab	humanized	IFN-α	SLE, dermatomyositis, polymyositis
Siltuximab	Sylvant®	mab	chimeric	IL-6	Multicentric Castleman's disease, cancer
Simtuzumab		mab	humanized	LOXL2	?
Siplizumab		mab	humanized	CD2	psoriasis, graft-versus-host disease (prevention)
Sirukumab		mab	human	IL-6	rheumatoid arthritis
Solanezumab		mab	humanized	β-amyloid	Alzheimer's disease
Solitomab		mab	mouse	EpCAM	?
Sonepcizumab		?	humanized	Sphingosine-1-phosphate	choroidal and retinal neovascularization
Sontuzumab		mab	humanized	Episialin	?
Stamulumab		mab	human	Myostatin	muscular dystrophy
Sulesomab	LeukoScan®	Fab'	mouse	NCA-90 (granulocyte antigen)	osteomyelitis (imaging)
Suvizumab		mab	humanized	HIV-1	viral infections
Tabalumab		mab	human	BAFF	B-cell cancers
Tacatuzumab tetraxetan	AFP-Cide®	mab	humanized	α-fetoprotein	cancer
Tadocizumab		Fab	humanized	Integrin αIIbβ3	percutaneous coronary intervention
Talizumab		mab	humanized	IgE	allergic reaction
Tanezumab		mab	humanized	NGF	pain
Taplitumomab paptox		mab	mouse	CD19	cancer[citation needed]
Tefibazumab	Aurexis®	mab	humanized	Clumping factor A	Staphylococcus aureus infection
Telimomab aritox		Fab	mouse	?	?
Tenatumomab		mab	mouse	Tenascin C	cancer
Teneliximab		mab	chimeric	CD40	?
Teplizumab		mab	humanized	CD3	diabetes mellitus type 1
Teprotumumab		mab	human	CD221	hematologic tumors
Ticilimumab (Tremelimumab)		mab	human	CTLA-4	cancer
Tildrakizumab		mab	humanized	IL23	immunologically mediated inflammatory disorders
Tigatuzumab		mab	humanized	TRAIL-R2	cancer
Tocilizumab (Atlizumab)	Actemra®, RoActemra®	mab	humanized	IL-6 receptor	rheumatoid arthritis
Toralizumab		mab	humanized	CD154 (CD40L)	rheumatoid arthritis, lupus nephritis etc.
Tositumomab	Bexxar®	mab	mouse	CD20	follicular lymphoma
Tovetumab		mab	human	CD140a	cancer
Tralokinumab		mab	human	IL-13	asthma etc.
Trastuzumab	Herceptin®	mab	humanized	HER2/neu	breast cancer
Tregalizumab		mab	humanized	CD4	?
Tremelimumab		mab	human	CTLA-4	cancer
Tucotuzumab celmoleukin		mab	humanized	EpCAM	cancer
Tuvirumab		?	human	Hepatitis B virus	chronic hepatitis B
Ublituximab		mab	chimeric	MS4A1	cancer
Urelumab		mab	human	4-1BB	cancer etc.
Urtoxazumab		mab	humanized	Escherichia coli	diarrhoea caused by E. coli
Ustekinumab	Stelara®	mab	human	IL-12, IL-23	multiple sclerosis, psoriasis, psoriatic arthritis
Vantictumab		mab	human	Frizzled receptor	cancer
Vapaliximab		mab	chimeric	AOC3 (VAP-1)	?
Vatelizumab		mab	humanized	ITGA2	?
Vedolizumab	Entyvio®	mab	humanized	Integrin α4β7	Crohn's disease, ulcerative colitis
Veltuzumab		mab	humanized	CD20	non-Hodgkin's lymphoma
Vepalimomab		mab	mouse	AOC3 (VAP-1)	inflammation
Vesencumab		mab	human	NRP1	?
Visilizumab	Nuvion®	mab	humanized	CD3	Crohn's disease, ulcerative colitis
Volociximab		mab	chimeric	Integrin α5β1	solid tumors
Vorsetuzumab mafodotin		mab	humanized	CD70	cancer
Votumumab	HumaSPECT®	mab	human	Tumor antigen CTAA16.88	colorectal tumors
Zalutumumab	HuMax-EGFr	mab	human	EGFR	squamous cell carcinoma of the head and neck
Zanolimumab	HuMax-CD4	mab	human	CD4	rheumatoid arthritis, psoriasis, T-cell lymphoma
Zatuximab		mab	chimeric	EGFR, HER1	cancer
Ziralimumab		mab	human	CD147 (basigin)	?
Zolimomab aritox		mab	mouse	CD5	systemic lupus erythematosus, graft-versus-host disease